

MAP17 (P-16): sc-27376

BACKGROUND

MAP17, also known as small PDZK1-associated protein (SPAP) and DD96, exists as a 12-17 kDa non-glycosylated membrane protein associated with various human carcinomas. MAP17 is also expressed in the proximal tubules of the kidney cortex and in the spermatids of the seminiferous tubules. MAP17 interacts with PDZK1, associates with the N-terminus of NaPi-IIa within the PDZK1/NaPi-IIa/MAP17 complex, and acts as an apical anchoring site for PDZK1.

REFERENCES

- Kocher, O., et al. 1996. Identification and partial characterization of a novel membrane-associated protein (MAP17) up-regulated in human carcinomas and modulating cell replication and tumor growth. *Am. J. Pathol.* 149: 493-500.
- Kocher, O., et al. 1998. Identification and partial characterization of PDZK1: a novel protein containing PDZ interaction domains. *Lab Invest.* 78: 117-125.
- Kocher, O., et al. 1999. PDZK1, a novel PDZ domain-containing protein up-regulated in carcinomas and mapped to chromosome 1q21, interacts with cMOAT (MRP2), the multidrug resistance-associated protein. *Lab Invest.* 79: 1161-1170.
- Pribanic, S., et al. 2003. Interactions of MAP17 with the NaPi-IIa/PDZK1 protein complex in renal proximal tubular cells. *Am. J. Physiol. Renal. Physiol.* 285: 784-791.
- Blasco, T., et al. 2003. Rat kidney MAP17 induces cotransport of Na/mannose and Na/glucose in *Xenopus laevis* oocytes. *Am. J. Physiol. Renal. Physiol.* 285: 799-810.
- Silver, D.L., et al. 2003. Identification of small PDZK1-associated protein, DD96/MAP17, as a regulator of PDZK1 and plasma high density lipoprotein levels. *J. Biol. Chem.* 278: 28528-28532.
- Kocher, O., et al. 2003. Targeted disruption of the PDZK1 gene by homologous recombination. *Mol. Cell Biol.* 23: 1175-1180.

SOURCE

MAP17 (P-16) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an internal region of MAP17 of human origin.

PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-27376 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

APPLICATIONS

MAP17 (P-16) is recommended for detection of MAP17 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for MAP17 siRNA (h): sc-72180.


Molecular Weight of MAP17: 12-17 kDa.

Positive Controls: HeLa whole cell lysate: sc-2200.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunoprecipitation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/2.0 ml). 3) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

DATA



MAP17 (P-16): sc-27376. Western blot analysis of MAP17 expression in non-transfected: sc-117752 (A) and human MAP17 transfected: sc-113472 (B) 293T whole cell lysates.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.